Outcomes-Based Contracts May Rely More On Patient-Reported Results
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.